Document Detail


Limitations of metformin use in patients with kidney disease: are they warranted?
MedLine Citation:
PMID:  20977579     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
AIM: To show that metformin, one of the most widely used agents, is contraindicated in patients with diabetes having chronic kidney disease (CKD) (i.e. serum creatinine >1.5 mg/dl) secondary to fear of lactic acidosis. The overall incidence of lactic acidosis is estimated at an upper limit of eight cases per 100 000 patient-years. We evaluated metformin use in two cohorts, one from the University of Chicago Diabetes Center and the other from National Health and Nutrition Examination Survey (NHANES) 1999-2006.
METHODS: Estimated glomerular filtration rate (eGFR) was calculated using the re-expressed Modification of Diet in Renal Disease (MDRD) Study equation and compared to serum creatinine. We hypothesized that metformin is used in patients with undetected advanced CKD (i.e. serum creatinine is ≥1.5 mg/dl). A chi-squared test was used to compare per cent differences of metformin use across demographic variables and eGFR in the NHANES cohort.
RESULTS: At the University of Chicago Diabetes Center, 36 of 234 (15.3%) patients with an eGFR of <60 ml/min/1.73 m(2) were receiving metformin. Data from NHANES, age >18 years and eGFR <60 ml/min/1.73 m(2) showed that Blacks with advanced nephropathy were three times more likely to receive metformin.
CONCLUSIONS: We conclude that metformin utilization occurs with a higher frequency than predicted by serum creatinine in people with eGFR <60 ml/min/1.73 m(2) . Given the very low incidence of lactic acidosis, the recommendation should be changed to reflect eGFR cut-off values rather than serum creatinine.
Authors:
K P Vasisht; S-C Chen; Y Peng; G L Bakris
Related Documents :
10398549 - United kingdom prospective diabetes study (ukpds): what now or so what?
11701439 - Inverse relationship between peripheral insulin removal and action: studies with metfor...
8864639 - Clinical profile of the novel sulphonylurea glimepiride.
10926309 - Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 dia...
19435959 - Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lif...
12879789 - [symbol: see text] nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
8098449 - Meta-analysis of effects of intensive blood-glucose control on late complications of ty...
10475589 - Vanadium and diabetes.
3294069 - Ontogeny of islet cell antibodies, insulin autoantibodies and insulitis in the non-obes...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  12     ISSN:  1463-1326     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  1079-83     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Division of Adult Endocrinology, Diabetes and Metabolism, and Hypertensive Diseases Unit, University of Chicago Hospitals, Chicago, IL 60637, USA. kavasisht@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in co...
Next Document:  Synergistic effects of ascorbic acid and thiazolidinedione on secretion of high molecular weight adi...